Krilogy Financial’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.23M Buy
9,704
+96
+1% +$12.6K 0.04% 336
2026
Q1
$1.33M Buy
9,608
+5,001
+109% +$700K 0.04% 292
2025
Q4
$635K Buy
4,607
+2,198
+91% +$267K 0.02% 475
2025
Q3
$295K Buy
+2,409
New +$274K 0.01% 691
2018
Q4
Sell
-3,728
Closed -$288K 338
2018
Q3
$288K Buy
3,728
+798
+27% +$60.3K 0.07% 116
2018
Q2
$208K Sell
2,930
-1,263
-30% -$89.2K 0.05% 137
2018
Q1
$316K Sell
4,193
-1,423
-25% -$113K 0.08% 115
2017
Q4
$402K Sell
5,616
-346
-6% -$26.3K 0.1% 97
2017
Q3
$483K Sell
5,962
-266
-4% -$20.3K 0.12% 80
2017
Q2
$441K Sell
6,228
-812
-12% -$54K 0.12% 75
2017
Q1
$504K Hold
7,040
0.16% 66
2016
Q4
$504K Buy
7,040
+665
+10% +$49.4K 0.16% 66
2016
Q3
$504K Sell
6,375
-309
-5% -$25.1K 0.16% 63
2016
Q2
$558K Buy
6,684
+256
+4% +$22.7K 0.19% 64
2016
Q1
$591K Buy
+6,428
New +$580K 0.24% 49
2015
Q4
Sell
-5,734
Closed -$563K 478
2015
Q3
$563K Buy
+5,734
New +$637K 0.27% 44

Other funds holding GILD

Krilogy Financial's GILD Position: Q2 2026 in Review

Krilogy Financial increased its Gilead Sciences (GILD) stake by 1% in Q2 2026, buying an estimated $12.6K and bringing the position to 9,704 shares worth $1.23M. The position accounts for 0.04% of the portfolio, ranked #336.

Krilogy Financial first reported a position in GILD in Q3 2015 and has held it in 16 quarters since. The position peaked at $1.33M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Krilogy Financial held 9,704 shares of Gilead Sciences worth $1.23M as of Q2 2026.
  • Krilogy Financial bought 96 Gilead Sciences shares in Q2 2026, an estimated $12.6K.
  • Gilead Sciences made up 0.04% of Krilogy Financial's portfolio in Q2 2026, its #336 holding.
  • Krilogy Financial first reported a position in Gilead Sciences in Q3 2015 and has held it in 16 quarters since.
  • Krilogy Financial's Gilead Sciences position peaked at $1.33M in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Krilogy Financial's 13F filing for Q2 2026, filed 27 Jul 2026.